Research programme: anaemia therapies - Transition TherapeuticsAlternative Names: Anemia therapies - Transition Therapeutics; Hypoxia inducible factor prolyl hydroxylase inhibitors - Transition Therapeutics
Latest Information Update: 24 Aug 2010
At a glance
- Originator Transition Therapeutics
- Mechanism of Action Mixed function oxygenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Anaemia
Most Recent Events
- 05 Jun 2008 Preclinical development is ongoing
- 15 Mar 2006 Preclinical trials in Anaemia in Canada (unspecified route)